SAB Biotherapeutics Income Statement (2020-2026) | SABS

Income Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
1.48M2.73M4.35M4.36M4.36M5.09M5.09M5.29M5.29M5.52M9.28M9.28M9.28M9.34M9.35M9.35M10.66M47.66M
Revenue & cost
Revenue (Quarter)
18.21M14.68M11.06M11.80M6.35M3.59M2.16M0.58M0.09M1.27M0.31M0.94M0.26M0.11M
Operating items
Research & Development (Quarter)
18.68M15.07M10.65M13.32M8.58M7.35M7.14M4.54M3.66M4.02M4.30M8.15M6.82M7.83M7.65M7.66M7.00M8.97M10.73M13.40M
Selling, General & Administrative (Quarter)
2.40M3.60M7.75M5.19M4.31M4.04M2.88M3.45M2.90M2.57M14.88M4.19M3.64M3.48M2.47M3.11M2.74M3.71M5.04M6.60M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
21.08M18.67M18.40M18.51M12.89M11.40M10.02M7.98M6.56M6.59M19.18M12.34M10.46M11.31M10.12M10.77M9.73M12.68M15.77M20.00M
Operating Income (Quarter)
-2.87M-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M
EBIT (Quarter)
-2.87M-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.00M0.01M0.01M0.02M0.02M0.03M0.06M0.03M0.01M0.48M0.50M0.37M0.28M0.14M0.06M0.01M0.66M0.70M1.05M
Other Non Operating Income (Quarter)
-0.07M0.00M0.00M7.79M1.67M0.00M0.03M0.10M0.34M0.48M0.37M0.75M0.85M0.55M0.30M0.77M1.53M0.63M
Non Operating Income (Quarter)
0.09M-0.07M-4.21M7.79M1.67M0.73M0.01M0.05M-0.40M0.22M-3.98M6.36M2.87M0.96M-1.39M5.58M-0.38M58.12M-1.09M1.13M
Net income details
EBT (Quarter)
-2.94M-4.06M-11.55M1.08M-4.87M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-10.00M-10.97M-10.45M-12.75M-14.57M-46.51M
Tax Provisions (Quarter)
0.09M-0.09M
Profit After Tax (Quarter)
-2.94M-4.06M-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M45.45M-16.86M-18.87M
Income from Non-Controlling Interests (Quarter)
0.07M0.08M-0.23M0.07M0.07M0.07M-0.21M0.07M0.07M0.07M-0.21M0.07M0.07M
Income from Continuing Operations (Quarter)
-2.94M-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-10.00M-10.97M-10.45M-12.75M-14.57M-46.51M
Consolidated Net Income (Quarter)
-2.94M-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-10.00M-10.97M-10.45M-12.75M-14.57M-46.51M
Income towards Parent Company (Quarter)
-2.94M-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-10.00M-10.97M-10.45M-12.75M-14.57M-46.51M
Net Income towards Common Stockholders (Quarter)
-2.94M-4.06M-11.55M0.99M-4.78M-7.08M-7.87M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-11.39M-5.20M-10.11M-12.75M-14.57M-18.87M
Additional items
EPS (Basic) (Quarter)
-6.62-2.75-4.230.23-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.09-1.20-0.33-0.35
EPS (Diluted) (Quarter)
-1.13-1.56-4.230.22-1.11-1.64-1.81-1.46-1.36-0.97-4.14-0.54-0.79-1.12-1.23-0.56-1.09-0.16-0.24-0.35
Shares Outstanding (Quarter)
0.44M1.48M2.73M4.31M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M10.66M44.79M53.56M
Shares Outstanding (Diluted) (Quarter)
2.60M2.60M2.73M4.58M4.30M4.30M4.35M5.04M5.04M5.24M5.52M9.24M9.26M9.26M9.26M9.29M9.29M77.86M61.34M53.56M
EBITDA (Quarter)
-2.87M-3.99M-7.34M-6.71M-6.54M-7.81M-7.86M-7.40M-6.48M-5.32M-18.87M-11.39M-10.20M-11.31M-10.01M-10.77M-9.73M-12.68M-15.77M-20.00M
Interest Expenses (Quarter)
0.28M0.28M0.92M0.31M2.15M0.35M1.06M0.12M1.66M0.44M-0.04M0.24M0.25M0.26M0.13M0.26M0.73M0.73M-0.50M27.56M
Tax Rate (Quarter)
8.561.90